Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study
Brain · 01.08.2024 · 147 (8) · 2668-2679
DOI: 10.1093/brain/awae142 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Brain, online erschienen am 30.07.2024. Verfasst von Lola Cook und 35 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Genetic Testing, Glucosylceramidase, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Parkinson's Foundation.
Abstract (Originalsprache)
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinson’s disease; however, individuals with Parkinson’s disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinson’s disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinson’s disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinson’s disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more ‘high risk factors’ for a genetic aetiology: early onset (<50 years), high-risk ancestry (Ashkenazi Jewish/Basque/North African Berber), an affected first-degree relative; and, importantly, in 9.1% of people with none of these risk factors. Reportable variants in GBA1 were identified in 7.7% of all participants; 2.4% in LRRK2; 2.1% in PRKN; 0.1% in SNCA; and 0.2% in PINK1, PARK7 or VPS35 combined. Variants in more than one of the seven genes were identified in 0.4% of participants. Approximately 13% of study participants had a reportable genetic variant, with a 9% yield in people with no high-risk factors. This supports the promotion of universal access to genetic testing for Parkinson’s disease, as well as therapeutic trials for GBA1 and LRRK2-related Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Parkinson's Foundation, NewYork, NY 10018, USA.
- Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland OH 44106, USA.
- The Ken & Ruth Davee Department of Neurology, Northwestern University, Chicago, IL 60611, USA.
- Struthers Parkinson's Center, Golden Valley, MN 55427, USA.
ORCID-Profile: Thomas F Tropea, Cornelis Blauwendraat, James C Beck, Roy N Alcalay
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Parkinson's Foundation
- Parkinson’s Foundation
Zitieren
APA
Cook, L., Verbrugge, J., Schwantes-An, T. H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., Schwarzschild, M. A., Simuni, T., Bressman, S., Wills, A. M., Fernandez, H. H., Litvan, I., Lyons, K. E., Shill, H. A., Singer, C., …, & Alcalay, R. N. (2024). Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study. Brain, 147(8), 2668-2679. https://doi.org/10.1093/brain/awae142
Vancouver
Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, et al. Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024;147(8):2668-2679. doi:10.1093/brain/awae142
BibTeX
@article{Cook2024,
author = {Cook, Lola and Verbrugge, Jennifer and Schwantes-An, Tae-Hwi and Schulze, Jeanine and Foroud, Tatiana and Hall, Anne and Marder, Karen S and Mata, Ignacio F and Mencacci, Niccolò E and Nance, Martha A and Schwarzschild, Michael A and Simuni, Tanya and Bressman, Susan and Wills, Anne-Marie and Fernandez, Hubert H and Litvan, Irene and Lyons, Kelly E and Shill, Holly A and Singer, Carlos and Tropea, Thomas F and Vanegas Arroyave, Nora and Carbonell, Janfreisy and Cruz Vicioso, Rossy and Katus, Linn and Quinn, Joseph F and Hodges, Priscila D and Meng, Yan and Strom, Samuel P and Blauwendraat, Cornelis and Lohmann, Katja and Casaceli, Cynthia and Rao, Shilpa C and Ghosh Galvelis, Kamalini and Naito, Anna and Beck, James C and Alcalay, Roy N},
title = {Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study},
journal = {Brain},
year = {2024},
volume = {147},
number = {8},
pages = {2668--2679},
doi = {10.1093/brain/awae142}
}
EUVIMED